Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor Inhibitors in Patients with Advanced Non-small Cell Lung Cancer  by Vollebergh, Marieke A. et al.
ORIGINAL ARTICLE
Ligands of Epidermal Growth Factor Receptor and the
Insulin-Like Growth Factor Family as Serum Biomarkers for
Response to Epidermal Growth Factor Receptor Inhibitors
in Patients with Advanced Non-small Cell Lung Cancer
Marieke A. Vollebergh, MD,*† Ingrid Kappers, MD,‡ Houke M. Klomp, MD, PhD,‡
Johanna C. Buning-Kager, BASc,§ Catharina M. Korse, MSc,§ Michael Hauptmann, PhD,
Karin E. de Visser, MSc, PhD,* Michel M. van den Heuvel, MD, PhD,¶
and Sabine C. Linn, MD, PhD*†
Introduction: The selection of patients with non-small cell lung
cancer (NSCLC) for epidermal growth factor receptor (EGFR)
inhibitor (EGFR-tyrosine kinase inhibitors [TKIs]) therapy is sub-
optimal as tumor tissue is often unavailable. Ligands of EGFR,
transforming growth factor-alpha (TGFa) and amphiregulin (ARG),
and the insulin-like growth factor (IGF) family have been associated
with resistance to EGFR-TKIs. The aim of our study was to explore
whether concentrations of these factors measured in serum were
predictive of response to EGFR-TKIs.
Methods: We assessed serum levels of marker candidates using
enzyme-linked immunosorbent (TGFa and ARG) and chemilumi-
nescent (IGF1 and IGF-binding protein-3) assays in 61 patients with
advanced NSCLC treated with EGFR-TKIs and 63 matched ad-
vanced NSCLC control patients without EGFR-TKIs treatment. We
dichotomized marker levels at the 20th, 50th, or 80th percentile and
evaluated whether the effect of EGFR-TKIs treatment on disease-
specific survival (DSS) differed by marker level based on multivar-
iate proportional hazards regression with an interaction term.
Results: The effect of EGFR-TKIs treatment on DSS showed a
significant difference by TGFa and ARG (interaction p  0.046 and
p  0.004, respectively). Low concentrations of TGFa and high
concentrations of ARG were associated with a better DSS in EGFR-
TKIs patients compared with control patients. Patients with high
concentrations of IGF-binding protein-3 had significantly longer
DSS, independent of treatment (hazard ratio: 0.60 per 1 mg/liter,
95% confidence interval: 0.46–0.79).
Conclusion: Our results suggest that concentrations of TGFa and
ARG measured in serum are predictive of EGFR-TKI response. The
combination of these two biomarkers could be of value in the
process of selecting patients for treatment with EGFR-TKIs.
Key Words: Non-small cell lung cancer, EGFR tyrosine kinase
inhibitors, EGFR ligands, Insulin-like growth factor, Serum
biomarkers.
(J Thorac Oncol. 2010;5: 1939–1948)
Non-small cell lung cancer (NSCLC) is the leading causeof cancer mortality worldwide. Small molecule inhibi-
tors competing with the adenosine triphosphate binding site
of the epidermal growth factor receptor (EGFR) tyrosine
kinase such as erlotinib and gefitinib (EGFR-tyrosine kinase
inhibitors [TKIs]) have proven their efficacy in the treatment
of NSCLC.1–4 These orally administered EGFR-TKIs showed
rapid tumor responses and improvements in quality of life in
patients with advanced NSCLC who were irresponsive to
platinum-based chemotherapy. Unfortunately, the response
rates of erlotinib and gefitinib are low in unselected patients
with NSCLC, and many studies tested EGFR for its predic-
tive potential. EGFR mutations and amplification of EGFR
were found to be predictive of response to EGFR-TKIs with
response rates of up to 70%.5–11 Nevertheless, there are
several reasons why selection based on EGFR mutation or
EGFR amplification status alone might not suffice. First,
stabilization of disease has not been correlated with the
presence of EGFR mutations or amplification, although this
treatment effect is considered beneficial in the management
of NSCLC.6,12 Second, no mutations were identified in 10 to
20% of patients with a partial response to gefitinib.(5,6,13–16)
Finally, to select patients based on EGFR mutations or
amplification, tumor tissue is required, which is often un-
available. Identifying new methods to select patients likely to
respond to EGFR-TKIs, therefore, remains important.
Many studies have tested ligands of EGFR in relation-
ship to EGFR-TKI response. Of the EGFR-specific ligands,
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transforming growth factor-alpha (TGFa) and amphiregulin
(ARG) have been studied intensively in vitro and in patients
in relationship to EGFR-TKI treatment.17–21 Gene expression
microarray studies showed that both TGFa and ARG were
overexpressed in tumors from patients with NSCLC not
responding to gefitinib.17 Subsequently, Ishikawa et al. and
Masago et al.18,21 found that serum measurements of TGFa
and ARG were predictive of overall survival and tumor
response in patients with advanced NSCLC treated with
gefitinib. Nevertheless, because a control group was missing,
differentiation between therapy benefit and survival benefit
remains unclear.
In addition to ligands of EGFR, insulin-like growth
factor (IGF) receptor type 1 (IGF1R) has been implicated in
resistance to EGFR-TKI treatment.22–25 Cross-talk between
IGF1R and EGFR has been reported, and overexpression of
IGF1R has been correlated with decreased efficacy of EGFR
targeting in a glioblastoma model.22 IGF1R is mainly acti-
vated by its ligand IGF1.26–28 The bioavailability of IGF1 is
regulated by a family of IGF-binding proteins (IGFBPs),
particularly IGFBP3, a major serum binding protein for
IGF1.26–28 Consequently, the IGF1:IGFBP3 ratio is com-
monly used as readout for the bioactivity of IGF1.26–31
As IGF1R is activated by IGF1, whose bioavailability
is regulated by IGFBP3, we hypothesize that serum concen-
trations of IGF1, IGFBP3, or the IGF1:IGFBP3 ratio might
be predictive of response to EGFR-TKIs, in addition to levels
of TGFa and ARG. The aim of this study, therefore, was to
explore whether concentrations of TGFa, ARG, IGF1, or
IGFBP3 measured in serum of patients with advanced
NSCLC were predictive of response to EGFR-TKIs. We
assessed serum levels of these candidate markers in pa-
tients treated with EGFR-TKI and a matched control group
of untreated patients. We evaluated whether the effect of
EGFR-TKI treatment on disease-specific survival (DSS)
differed by marker level based on multivariate propor-
tional hazards regression with an interaction term.
PATIENTS AND METHODS
Patient Selection
In this retrospective study, we studied patients with
advanced NSCLC who had been enrolled between 2001 and
2005 in an Expanded Access Program. Patients had been
treated on a compassionate use basis with gefitinib or erlo-
tinib (EGFR-TKI) at the Netherlands Cancer Institute (NKI).
Patients without brain metastases were eligible for this pro-
gram in case of no response to conventional chemotherapy or
unavailability of alternative treatment options.11 Written in-
formed consent was obtained from all patients. The inclusion
criteria for this study consisted of EGFR-TKI treatment for
more than 14 days and availability of serum collected within
100 days before start of treatment. To differentiate between
prognostic and predictive value of the ligands, a control
group of patients was identified, not treated with EGFR-TKIs
and matched for gender, age, and histology to the EGFR-TKI
treated patients. Controls were diagnosed between 1995 and
2006. In total, 124 patients were included in this study, which
was designed following the REMARK guidelines.32 This
translational study was approved by the Institutional Review
board of the NKI.
Treatment
Patients receiving gefitinib were treated with a daily
dose of 250 mg. Erlotinib was dosed at 150 mg daily, dose
reductions to 50 mg occurred due to severe toxicity (n  2).
Treatment with EGFR-TKIs was continued until disease
progression or the occurrence of a serious adverse event.
Serum Analyses
Serum was stored at30°C. TGFa concentrations were
measured using a commercially available enzyme-linked im-
munosorbent assay (ELISA; ELISA-kit, DTGA00, R&D sys-
tems, MN) according to manufacturer’s instruction. A stan-
dard curve was prepared for each plate using human
recombinant TGFa diluted in assay diluent (provided by the
ELISA-kit) for reference. The minimum detection limit of the
assay was 3.0 ng/liter. For detection of ARG, an ELISA
research kit (DY262, R&D systems) was used according to
manufacturer’s instructions (validation experiments Appen-
dix). In short, 96-well clear flexible microtiter plates (DY990,
R&D systems) were coated with 2 mg/liter capturing anti-
body overnight. After washing with phosphate-buffered sa-
line (PBS) (pH, 7.4) containing 0.05% Tween20, wells were
blocked with 300 l reagent diluent (DY995, R&D systems)
for 1 hour and washed again. Subsequently, wells were
incubated for 2 hours with serum samples. After washing, the
wells were incubated for 2 hours with 100 g/liter biotinyl-
ated goat antihuman ARG (DY262, R&D Systems) followed
by washing and a 20-minute reaction with streptavidin-con-
jugated horseradish-peroxidase. After washing, 100 l sub-
strate solution (DY 999, R&D systems) was added for 20
minutes. The color reaction was stopped by adding 50 l 2 N
sulfuric acid. Color intensity was determined at a wavelength
of 450 nm with reference wavelength of 540 nm. The stan-
dard curve was drawn for each plate using recombinant ARG
diluted in 10% fetal calf serum in PBS. Minimum detection
limit of the assays for serum ARG was 3.0 ng/liter (validation
experiments Appendix).
For the concentrations of IGF1 and IGFBP3, fully
automated chemiluminescent immunometric technology was
used (Immulite 2000, Siemens Medical Solutions Diagnos-
tics). To calculate the IGF1:IGFBP3 ratio, IGFBP3 (mg/liter)
was converted to molar concentrations with a conversion
factor of 34.78. The normal range provided by the manufac-
turer for the age group 61 to 65 years was 9.75–27.56
nmol/liter for IGF1 and 3.2 to 6.6 mg/liter for IGFBP3.
Statistical Analyses
DSS was defined as the time from start of treatment
with the EGFR-TKI to death of disease or end of follow-up.
Patients who were still alive at the end of follow-up, lost to
follow-up, or who died due to non-NSCLC causes were
censored at that time. For the control group, DSS was
calculated from the start of first treatment (radiotherapy or
chemotherapy) in the NKI or date of first visit if no treatment
was started within the NKI.
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Differences in clinicopathological variables between
the EGFR-TKI group and the control group were tested using
Fisher’s exact test tests, Kruskal-Wallis tests, exact Mann-
Whitney U tests, and Student’s t tests. Patients with missing
values for a variable were excluded from analyses involving
that variable. Correlation between levels of candidate mark-
ers and age, and serum storage time were calculated using
Spearman’s rank and Pearson correlation analyses. Associa-
tions between marker candidates and gender, stage (III, IV),
smoking status (smoker, nonsmoker), performance status
(World Health Organization 0–1, 2–3), and histology (ade-
nocarcinoma, other) were investigated by means of Mann-
Whitney U tests and Student’s t tests.
We evaluated whether the effect of EGFR-TKI treat-
ment on DSS, expressed as hazard ratio (HR), differed by
candidate marker level based on multivariate proportional
hazards regression with an interaction term, adjusting for
potential confounders (gender, smoking, prior chemotherapy,
stage, and histology). Instead of searching for an optimal
cutoff, we a priori selected three alternative cutoffs (20th,
50th, or 80th percentile) to dichotomize marker levels. For all
cutoffs, interaction terms were calculated using the multivar-
iate model; the cutoff with the largest absolute interaction
coefficient was evaluated for the proportional hazards as-
sumption by adding interaction terms between the time-
dependent natural logarithm of follow-up time plus one and
the interaction between treatment and candidate markers
(p value between 0.33 and 0.92). No evidence for nonpropor-
tional hazards was found, and the cutoffs of these candidate
markers were further evaluated. Direct adjusted survival
curves based on a multivariate Cox regression model includ-
ing prior chemotherapy, performance status, and smoking and
stratified for treatment were calculated using a SAS macro by
Zhang et al.33 All other calculations were performed using the
statistical package SPSS (version 15.0 for Windows).
RESULTS
Sixty-one EGFR-TKI treated patients were eligible for
this study (Figure 1). The control group consisted of 63
patients, matched for gender, age, and histology as presented
together with other clinical and pathologic characteristics in
Table 1. Patients treated with EGFR-TKIs were significantly
more often never smokers (p  0.03), had more stage IIIa/b
disease (p  0.01, Table 1), and presented more often with a
poor performance status (p  0.05). Furthermore, this group
had significantly more often received prior chemotherapy
(p  0.01, Table 1). All four marker candidates could be
tested in all 124 patients. IGF1, IGFBP3, and the IGF1:
IGFBP3 ratio showed a Gaussian distribution, whereas TGFa
and ARG were lognormal distributed. Factors were not cor-
related with serum storage time (Supplementary Figure 1,
http://links.lww.com/JTO/A48), age, stage, histology (data
not shown), or prior chemotherapy (Supplementary Figure 2,
http://links.lww.com/JTO/A49). Women had significantly
higher concentrations of TGFa (Mann Whitney U, p  0.03),
whereas patients with higher levels of IGFBP3 were signifi-
cantly more often nonsmokers (Student’s t test, p 0.03) and
had a better performance status (Student’s t test, p  0.005,
Supplementary Figure 2).
Smoking, prior chemotherapy, and performance status
were significantly associated with DSS (Supplementary Table 1,
http://links.lww.com/JTO/A52) and were, therefore, included in
multivariate analyses as potential confounders. The 20% cutoff
yielded the largest interaction coefficient in the multivariate
model for IGF1 and IGFBP3. Similarly, the median cutoff for
ARG and the 80% cutoff for TGFa and IGF1:IGFBP3 ratio
proved to be the largest (data not shown). These cutoffs were
selected for further analyses.
The effect of EGFR-TKI treatment differed signifi-
cantly between patients with high and low levels of TGFa
(interaction p  0.05). Among patients with low levels of
TGFa, the risk of death was almost twofold significantly
decreased after EGFR-TKI treatment compared with the
control group (Figure 2A, HR: 0.55, 95% confidence interval
[CI]: 0.32–0.96, p  0.04, Table 2), whereas in patients with
high levels of TGFa, this risk was nonsignificantly increased
(Figure 2A, HR: 1.51, 95% CI: 0.58–3.91, p 0.40, Table 2).
ARG interacted significantly with the effect of EGFR-
TKI treatment on DSS (interaction p 0.01). In patients with
high levels of ARG, EGFR-TKI treatment significantly de-
creased the risk of death more than threefold compared with
the control patients (Figure 2B, HR: 0.31, 95% CI: 0.15–0.63,
p  0.01, Table 2). No significant difference between both
Serum analyses of four candidate markers
Expanded access program
EGFR-TKI treatment > 14 days
Serum available within 100 days before 
start EGFR-TKI
Erlotinib (n=25)
EGFR-TKI group (n=61)* Control group (n=63)†
Erlotinib (n=63)
No EGFR-TKI treatment
Availability of serum (1995 - 2006) 
Matched for: gender, age and histology
Gefitinib (n=36)
Gefitinib (n=226)
FIGURE 1. Flow chart. Flow chart of patient se-
lection. *Included in epidermal growth factor re-
ceptor-tyrosine kinase inhibitor (EGFR-TKI) group:
EGFR-TKIs treatment 12 days (n  1). †Included
control group: 9 days of EGFR-TKIs treatment be-
fore death of disease (n  1).
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groups was found in patients with low ARG levels (Figure
2B, HR: 1.14, 95% CI: 0.59–2.17, p  0.70).
We observed a borderline significant benefit from
EGFR-TKI treatment (interaction p  0.09) among patients,
whose IGF1 levels exceeded the 20th percentile (Figure 2C,
HR: 0.48, 95% CI: 0.27–0.83, p  0.01, Table 2) but not
among others (Figure 2C, HR: 1.27, 95% CI: 0.45–3.53, p 
0.65, Table 2).
EGFR-TKI treatment effects differed less strongly by levels
of IGF1:IGFBP3 ratio or IGFBP3, and homogeneity was not
rejected (Supplementary Table 2, http://links.lww.com/JTO/
A53). Because IGFBP3 was significantly associated with per-
formance status, a strong prognostic factor, we studied whether
IGFBP3 was independently associated with DSS, regardless of
treatment. We evaluated this factor as a continuous variable
while adjusting for treatment. We observed a 40% decrease in
risk per 1 mg/liter IGFBP3 increase (HR: 0.60, 95% CI: 0.46–
0.79, p  0.001, Table 3).
As the EGFR-TKI treated patients and the control
patients were imbalanced for two important prognostic fac-
tors (i.e., prior chemotherapy and performance status), we
subsequently repeated the analyses of TGFa, ARG, and IGF1
in patients who had not received prior chemotherapy only
(number of EGFR-TKI treated patients and controls reduced
from 61 and 63 to 29 and 57, respectively) and in patients
with a good performance status only (number of EGFR-TKI
treated patients and controls reduced to 37 and 49, respec-
tively). We observed very similar patterns of treatment-
related HRs by serum marker levels (Supplementary Table 3,
http://links.lww.com/JTO/A54).
DISCUSSION
In this study, we determined whether concentrations of
TGFa, ARG, IGF1, IGFBP3, or the IGF1:IGFBP3 ratio
measured in serum were predictive of EGFR-TKI response
by comparing the DSS in patients treated with EGFR-TKIs
compared with matched EGFR-TKIs untreated patients. We
observed that patients with low serum concentrations of
TGFa or high serum concentrations of ARG significantly
benefited from EGFR-TKI treatment, whereas there was no
such evidence for patients with higher and lower respective
TABLE 1. Patient Characteristics
Total, n
(%)
Treatment
p
EGFR-TKI
Treated
Patients, n
(%)
Control
Patients, n
(%)
Total 124 (100) 61 (100) 63 (100)
Gender
Male 68 (55) 33 (54) 35 (56) 1.000a
Female 56 (45) 28 (46) 28 (44)
Age at treatment
65 yr 73 (59) 34 (56) 39 (62) 0.584a
65 yr 51 (41) 27 (44) 24 (38)
Smoking
Never smoked 16 (13) 12 (20) 4 (6) 0.029a
(Former) smoker 102 (82) 44 (72) 58 (92)
Unknown 6 (5) 5 (8) 1 (2)
Performance status
0–1 86 (69) 37 (61) 49 (78) 0.052a
2–3 29 (23) 19 (31) 10 (16)
Unknown 9 (7) 5 (8) 4 (6)
Histology
Large cell 31 (25) 13 (21) 18 (29) 0.673b
Squamous cell 20 (16) 9 (15) 11 (17)
Adenocarcinoma 59 (48) 32 (52) 27 (43)
Bronchoalveolar
carcinoma
6 (5) 3 (5) 3 (5)
Unknown 8 (6) 4 (7) 4 (6)
Stage of disease
IIIa/IIIb 20 (16) 16 (26) 4 (6) 0.003a
IV 104 (84) 45 (74) 59 (94)
TNM, T status
T1–T2 46 (37) 16 (26) 30 (48) 0.356a
T3–T4 34 (27) 16 (26) 18 (29)
Tx and unknown 44 (35) 29 (48) 15 (24)
TNM, N status
N0–N1 11 (9) 6 (10) 5 (8) 0.310a
N2–N3 61 (49) 21 (34) 40 (63)
Nx and unknown 52 (42) 34 (56) 18 (29)
Prior chemotherapy
No 86 (69) 29 (48) 57 (90) 0.001a
Yes 38 (31) 32 (52) 6 (10)
Disease-specific
survival
Range (d) 12–1638 16–1638 12–865
Median (d) 151 115 171 0.156c
TGFa
Range (ng/liter) 0–135.0 0–135.0 0–73.8
Median (ng/liter) 10.5 11.1 9.6 0.383c
ARG
Range (ng/liter) 0–2034.0 0–2034.0 0–1143.2
Median (ng/liter) 9.5 8.7 9.8 0.476c
IGF1
Range (nmol/liter) 2.74–43.07 4.61–39.51 2.74–43.07
Median (nmol/liter) 17.55 17.35 17.60 0.815d
TABLE 1. (Continued)
Total, n
(%)
Treatment
p
EGFR-TKI
Treated
Patients, n
(%)
Control
Patients, n
(%)
IGFBP3
Range (mg/liter) 1.46–6.24 1.46–5.81 1.59–6.24
Median (mg/liter) 3.92 3.93 3.91 0.800d
a p values calculated using Fisher’s exact test.
b p values calculated using Exact Kruskal-Wallis test.
c p values calculated using Exact Mann-Whitney U test.
d p values calculated using Student’s t test.
TGFa, transforming growth factor-alpha; ARG, amphiregulin; IGF1, insulin-like
growth factor-1; IGFBP3, insulin-like growth factor binding protein-3; EGFR-TKI, epider-
mal growth factor receptor tyrosine kinase inhibitor; TNM, tumor, node, metastasis.
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values. Whether serum concentrations of IGF1 are predictive
of response to EGFR-TKIs remains unclear, although our
data suggest this may be the case.
Our study confirms previous findings in which patients
with high levels of TGFa do not benefit from EGFR-TKI
treatment. More specifically, two Japanese groups found high
levels of both TGFa and ARG to be associated with progres-
sive disease and a worse overall survival after gefitinib
treatment in patients with NSCLC.18,21 Because both studies
lacked a control group, it was impossible to determine
whether this difference in survival was due to therapy (pre-
diction) or to tumor features (prognosis). Furthermore, both
studies looked for an optimal threshold using internal data.
Our results regarding ARG do not correspond with the
findings mentioned earlier. Instead of a worse DSS, we
observed a statistically significant benefit from EGFR-TKIs
in patients with high-serum ARG levels compared with the
control group but not among patients with low levels; this
difference was statistically significant. This different direc-
tion of ARG has previously been observed. In vitro, primarily
gefitinib-sensitive head and neck cancer cell lines were
shown to secrete ARG.34 Yonesaka et al.35 showed that
high-ARG expression as assessed by immunohistochemistry
was associated with stable disease in patients with NSCLC
treated with erlotinib or gefitinib, whereas low expression
was associated with progressive disease. Furthermore, in
patients with colorectal cancer treated with cetuximab (mono-
clonal antibody against EGFR), high-ARG expression by
microarray analyses was associated with disease control (re-
sponse and stable disease) and longer progression-free sur-
vival.36,37 The discrepancy between our findings of ARG and
both Japanese serum studies could be explained by the
different ethnicity of the study populations. Patients with
NSCLC from Asian origin are known to harbor EGFR mu-
tations more frequently.38,39 Subsequently, it is thought that
these tumors may have a distinct pathogenesis in which
A
B
C
Candidate marker above the cut-off Candidate marker below the cut-off
TGFa 80% 
EGFR-TKI
Control
(21.69ng/L) 
ARG median
(26.51ng/L) 
EGFR-TKI 
Control
IGF1 20%
(11.95nmol/L) 
EGFR-TKI 
Control
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FIGURE 2. Relationship of candi-
date markers with outcome in epi-
dermal growth factor receptor-ty-
rosine kinase inhibitor (EGFR-TKI)
treated patients and their matched
controls. Direct adjusted survival
curves based on a multivariate Cox
regression model including prior
chemotherapy, performance status,
and smoking and stratified for treat-
ment. A, Disease-specific survival
(DSS) according to transforming
growth factor-alpha (TGFa) levels
above and below 80th percentile
among patients treated with EGFR-
TKIs and their matched controls. B,
DSS according to amphiregulin
(ARG) levels above and below the
median among patients treated with
EGFR-TKIs and their matched con-
trols. C, DSS according to insulin-like
growth factor (IGF)1 above and be-
low 20th percentile among patients
treated with EGFR-TKIs and their
matched controls.
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tumors become completely dependent on the EGFR-pathway
through mutations.38,39 We speculate that high-ARG levels
might represent a different pathogenic pathway in patients
with NSCLC of white origin that leads to similar dependence
on this pathway, albeit less complete. As a consequence,
treatment of patients with high-ARG levels with EGFR-TKIs
might lead to cell cycle arrest (i.e., stable disease) but not, as
with EGFR mutations, to apoptosis (i.e., partial response and
complete response) as has been described in cell line stud-
ies.35,40 Furthermore, this could explain the rapid progression
of disease (“tumor flare”) after discontinuation of EGFR-
TKIs41 as has also been documented in gastrointestinal stromal
tumors after withdrawal of the BCR-ABL TKI imatinib.42
In addition to ligands of EGFR, we studied components
of the IGF1R-pathway. To the best of our knowledge, this is
the first study evaluating the relationship between benefit
from EGFR-TKIs and IGF1, IGFBP3, and the IGF1:IGFBP3
ratio. IGF1 is known to stimulate cell proliferation and to
inhibit apoptosis by binding to IGF1R, a receptor tyrosine
kinase.27,43 Activation of IGF1R leads to signaling of the
proliferative Ras-Raf-MAPK pathway and of the prosurvival
phosphoinositol-3 kinase (PI3K)-Akt pathway.27,43 Failure to
down-regulate Akt characterizes insensitivity to EGFR-TKIs
and has been shown to be mediated through PI3K signaling
by IGF1R.22–25,44,45 Furthermore, the combined use of anti-
IGF1R and EGFR-TKIs has been shown to be more effective
in vitro and in vivo than a single-agent approach.25,46 In our
study, patients with especially low levels of IGF1 did not
seem to benefit from EGFR-TKIs. We speculate that truly
low levels of IGF1 are the result of a negative-feedback loop
TABLE 2. Multivariate Cox Proportional-Hazard Regression Analysis of the Risk of Death (Disease-Specific Survival) per Factor
of Interest
Variables
TGFa ARGa IGF1b
No. of
Events/No.
of Patients
Hazard
Ratio 95% CI p
No. of
Events/No.
of Patients
Hazard
Ratio 95% CI p
No. of
Events/No.
of Patients
Hazard
Ratio 95% CI p
Smoking
(Former) smoker 95/102 1.00 95/102 1.00 95/102 1.00
Never smoked 13/16 0.76 0.38–1.52 0.440 13/16 0.59 0.29–1.16 0.127 13/16 0.59 0.30–1.16 0.123
Prior chemotherapy
No 79/86 1.00 79/86 1.00 79/86 1.00
Yes 35/38 2.97 1.68–5.23 0.001 35/38 3.47 1.98–6.09 0.001 35/38 3.78 2.17–6.61 0.001
Performance status
0–1 78/86 1.00 78/86 1.00 78/86 1.00
2–3 27/29 2.51 1.53–4.10 0.001 27/29 2.97 1.76–5.00 0.001 27/29 2.43 1.50–3.94 0.001
Ligand concentration
Low 90/99 1.00 56/62 1.00 22/25 1.00
High 24/25 1.41 0.74–2.68 0.296 58/62 1.88 1.07–3.30 0.029 92/99 0.73 0.31–175 0.481
Ligand concentration high
Control 13/14 1.00 31/33 1.00 49/53 1.00
EGFR-TKI treatment 11/11 1.51c 0.58–3.91 0.399 27/29 0.31a 0.15–0.63 0.001 43/46 0.48b 0.27–0.83 0.009
Ligand concentration low
Control 44/49 1.00 26/30 1.00 8/10 1.00
EGFR-TKI treatment 46/50 0.55c 0.32–0.96 0.035 30/32 1.14a 0.59–2.17 0.702 14/15 1.27b 0.45–3.53 0.654
a Homogeneity of both hazard ratios was rejected based on an interaction term with p  0.004 (ARG: cutoff at median ligand low 9.49 ng/liter; ligand high 9.49 ng/liter).
b Homogeneity of both hazard ratios was not rejected based on an interaction term with p  0.087 (IGF1: cutoff at 20% ligand low 11.95 nmol/liter; ligand high 11.95
nmol/liter).
c Homogeneity of both hazard ratios was rejected based on an interaction term with p  0.046 (TGFa: cutoff at 80% ligand low 21.69 ng/liter; ligand high 21.69 ng/liter).
TGFa, transforming growth factor-alpha; ARG, amphiregulin; IGF1, insulin-like growth factor-1; CI, confidence interval; EGFR-TKI, epidermal growth factor receptor tyrosine
kinase inhibitor.
TABLE 3. Multivariate Cox Proportional-Hazard Regression
Analysis of Death (Disease-Specific Survival) According to
IGFBP3, Independent of Treatment
Variables
No. of
Events
Hazard
Ratio 95% CI p
Smoking
(Former) smoker 95 1.00
Never smoked 13 0.88 0.43–1.79 0.726
Prior chemotherapy
No 79 1.00
Yes 35 3.66 2.12–6.31 0.001
Performance status
0–1 78 1.00
2–3 27 2.04 1.26–3.31 0.004
Ligand concentration
IGFBP3 per 1 mg/liter 114 0.60 0.46–0.79 0.001
Treatment
Control 57 1.00
EGFR-TKI treatment 57 0.56 0.34–0.94 0.027
IGFBP3, insulin-like growth factor binding protein-3; CI, confidence interval;
IGFBP3, insulin-like growth factor binding protein-3; EGFR-TKI, epidermal growth
factor receptor tyrosine kinase inhibitor.
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as the consequence of a constitutively active IGF1R-pathway
in these patients. This negative regulation has not been
documented but the opposite has in centennials, in whom a
mutation in IGF1R was associated with reduced activity of
IGF1R and high serum levels of IGF1.47 Consequently,
tumors of patients with low IGF1 may be able to sustain the
prosurvival signals through Akt activation by depending on
the IGF1R pathway for PI3K signaling instead of the EGFR
pathway. The only study reporting on the relationship be-
tween the IGF1R pathway, in the form of IGF1R expression
assessed by immunohistochemistry, and response to gefitinib
showed no association with gefitinib resistance.48 These re-
sults cannot directly be compared with our results, as we
studied different components of the IGF1R pathway using
different techniques.
Although studying prognostic factors was not an objec-
tive of our study, we found that IGFBP3 serum levels pre-
dicted DSS in patients with advanced NSCLC regardless of
treatment. The protective effect of high-IGFBP3 levels could
be explained not only by its ability to decrease the mitogenic
action and inhibit the antiapoptotic effect of IGF1 but also by
its IGF-independent inhibitory effect on cell growth.26,28,49–51
Our results confirm findings of a previous study in which
high-IGFBP3 plasma levels were associated with a significantly
longer overall survival in patients with advanced NSCLC treated
with irinotecan and cisplatin.52 Furthermore, reduced IGFBP3
expression assessed by immunohistochemistry was associated
with shorter DSS in patients with stage I NSCLC.53 Use of
serum IGFBP3 as a prognostic marker in stage I/II NSCLC
would be appealing and warrants further study.
Our study was relatively small, and therefore, our
evaluation could not attain the rigor of a training/validation
study or a large randomized controlled trial. Furthermore, the
EGFR-TKI group was not entirely homogeneous, as patients
treated with gefitinib or erlotinib were included. Neverthe-
less, these agents act by similar mechanisms, and sensitivity
analyses by drug, although based on small numbers, were
largely consistent with the combined results. Therefore, as
this is an exploratory study of candidate markers, we believe
that we have assembled a sufficiently large data set to
discover potentially predictive markers and have limited the
number of cutoffs to avoid substantial overfitting. The retro-
spective nature of our study did not allow for a standardized
measure for progression-free survival, which is considered to
be more directly linked to response. This was due to the fact
that imaging was not performed at set intervals. Nevertheless,
using data of documented radiologic progression (or if un-
available, data of clinical progression) for progression-free
survival resulted in very similar patterns of HRs for TGFa,
ARG, or IGF1 (data not shown). Furthermore, until now,
known markers predicting for response and progression-free
survival, such as EGFR mutations, have not been shown to
predict for an overall or DSS benefit after EGFR-TKIs in
randomized controlled trials,9,15,54 whereas this remains the
ultimate goal in patient treatment. We, therefore, consider the
presented data adequate to inform us whether and for which
markers further studies are indicated. Although EGFR-TKIs
response depends partly on presence of EGFR mutations or
EGFR amplifications, the two markers we identified could
greatly improve the prediction of EGFR-TKIs response in
two ways. First, not all patients who respond to EGFR-TKIs
are identified by EGFR mutations or amplifications, resulting
in withholding patients with advanced NSCLC potential sur-
vival benefit from EGFR-TKIs (undertreatment). In this
mostly palliative setting with limited treatment options, un-
dertreatment would seem worse than overtreatment, which
can be justified to some extent. Consequently, limiting un-
dertreatment by identification of a subgroup of patients resis-
tant to EGFR-TKIs seems just as or even more important.
Second, serum measurements do not require tumor tissue,
which is often unavailable, therefore greatly facilitating the
prediction.
In conclusion, by using a matched control group, we
were able to evaluate EGFR-TKI treatment benefit by marker
level. Our results suggest that concentrations of TGFa and
ARG measured in serum are predictive of EGFR-TKI re-
sponse. This is the first study in patients with NSCLC of
white origin in which this effect was evaluated and observed.
The combination of these two biomarkers could be of value
in the process of selecting patients for treatment with EGFR-
TKI. The optimal cutoff for TGFa and ARG, the use of the
combination of these two biomarkers as a predictive marker,
and its additive value to known clinical predictors for EGFR-
TKI resistance warrants further investigation and validation,
preferably in a prospective randomized controlled trial.
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APPENDIX: VALIDATION AMPHIREGULIN
DY262, R&D SYSTEMS
Results
All samples were analyzed in duplicate on the same
plate. Minimum detection limit of the assays for serum ARG
was 3.0 ng/liter. The interassay variability of this ELISA was
20% (concentrations in the low range) and 8.5% (concentra-
tions in the high range). The results shown earlier are a
representation of all the validation tests we have run. Using
reagents diluent of R&D, the recovery linearity of the assay
ranged between 49% and 121%, with an average of 105% of
the expected concentration. Nevertheless, when samples were
diluted using 10% FCS/PBS, no signal intensity of endoge-
nous ARG could be measured for 15 of 18 samples, whereas
in three samples, a signal was present (data not shown). The
recovery was determined by spiking in 200 ng/liter of recom-
binant ARG into serum samples. The range was between 76%
and 102%, with an average of 93.6% of the expected con-
centration when reagents diluent of R&D was used.
Conclusion
Although the recovery linearity of reagents diluent had
a wide range, this was partly due to the samples with high
Journal of Thoracic Oncology • Volume 5, Number 12, December 2010 Ligands of EGFR and the IGF
Copyright © 2010 by the International Association for the Study of Lung Cancer 1945
concentrations of ARG (220 ng/liter) in which low-recov-
ery linearity percentages arose. Nevertheless, the second
dilution step of these higher concentrated samples did seem to
be linear with the first dilution step. The results with fetal calf
serum dilutions were unexpected. We suspect that the endog-
enous “free” ARG is bound by binding proteins in the FCS.
We did not perform any additional experiments to prove this
hypothesis, as this was beyond the scope of our research.
Given the above findings, we proceeded the serum analysis
for ARG as described in the methods section and as described
many times in literature.55–60
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